Skip to main content

Equaly is a start-up rooted on innovative science for applications in the treatment of immunological disorders. We are developing and licensing treatment solutions based on patent-protected technology platforms aiming at

1) eliminating immunogenicity of therapeutic biologicals,

2) generating target-specific cytoxic cells to eradicate intracellular infections and tumors

3) modulating innate immunity to treat chronic inflammation and auto-immune diseases.

We are also looking for early-stage local and international partnerships to develop “translational” programs to support our platforms, including genomics, diagnostics & immune therapy. More to read on


CEI, Chemin du Cyclotron 6,

François Boitquin, CEO